Exercise And Rosuvastatin Treatment: Is There an Anti-Inflammatory Synergy?

NCT ID: NCT00295373

Last Updated: 2007-04-20

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-02-28
• Study Completion Date: 2007-08-31

Brief Summary

The purpose of this study is to determine whether the effects of rosuvastatin treatment and exercise training can be synergistic, with respect to the innate immune receptor TLR4, markers of systemic inflammation, and stimulated production of inflammatory cytokines, in hypercholesterolemic subjects. It is hypothesized that a rosuvastatin and exercise intervention will synergistically lower measured variables, so as to be anti-inflammatory.

Detailed Description

Both statin drugs and exercise training are known to exert anti-inflammatory effects. We found that both high levels of physical activity and an exercise training program reduced markers of inflammation and lowered monocyte Toll-like receptor 4 (TLR4) expression. It has not been determined whether statins exert their anti-inflammatory effects through the toll-like receptors or whether combined statin/exercise treatment will exert synergistic anti-inflammatory effects. Thus, the primary purposes of this study are two-fold: 1) Determine whether rosuvastatin treatment downregulates LPS-induced inflammatory responses, serum hsCRP, and monocyte TLR4 expression in hypercholesterolemic patients; and 2) Determine whether adding exercise training to rosuvastatin treatment induces an anti-inflammatory synergy and further lowers LPS-induced inflammatory response, hsCRP, and TLR4 expression. Thirty two hypercholesterolemic (total cholesterol > 200 mg/dL, LDL > 130 mg/dL) will be randomly divided into two groups: statin (ST) and statin and exercise (ST+E). Sixteen physically active, no-statin subjects will also be recruited as a control group(CON). After baseline blood sampling, ST and ST+E groups will begin a 10-week course of rosuvastatin calcium treatment (10 mg/d) after which a second blood sample will be obtained. The ST+E group will then begin a 10 week (three days per week) combined endurance (20 min at 70% of heart rate reserve) and resistive training (2 sets of 10 upper- and lower-body exercises) program. The ST group will not exercise and both ST+E and ST groups will continue taking their medication, as prescribed. A final blood sample will be taken at the end of this 10-week segment. Blood samples will also be taken from the CON group at 0, 10 and 20 weeks. Monocyte expression of TLR4, CD14 (LPS receptor) and CD16 (monocyte maturation marker) will be assessed using flow cytometry. LPS-stimulated inflammatory cytokine production and serum levels of hsCRP, TNF-a, oxLDL, LDL, HDL, endotoxin, LPS binding protein, and sCD14 will also be measured at each time point (baseline, 10 weeks, 20 weeks). These experiments will allow us to determine whether rosuvastatin downregulates TLR4, an important mediator of inflammation, and whether exercise, known to lower TLR4 expression, can augment the rosuvastatin effects. Regular exercise and statin treatment are known to reduce disease risk, but the benefits of these treatments is infrequently attributed to their anti-inflammatory effects. It is important to document mechanisms of anti-inflammatory action for exercise training and statin treatment and to determining whether these treatments have combined beneficial effects.

Conditions

Nonfamilial Hypercholesterolemia; Physical Inactivity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Rosuvastatin

Intervention Type: DRUG

Exercise Training

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Nonfamilial hypercholesterolemia
• Total cholesterol >200 mg/dl, LDL >130 mg/dL
• Physical inactivity
• Moderate to low alcohol intake

Exclusion Criteria

• Liver or kidney disease
• Acute illness or infection
• Use of corticosteroids, ACE inhibitors, platelet aggregating inhibitors, thiazolidinediones, and bis-phosphonates.
• Use of cyclosporine, warfarin, gemfibrozil or other lipid lowering agents
• Regular antacid or aspirin use
• Type I & II diabetes with insulin treatment
• hypothyroidism, and/or renal insufficiency
• Chronic/debilitating osteoarthritis
• Rheumatoid arthritis
• Central or peripheral nervous system disorders
• Anti-depressant medications
• Major affective disorder
• HIV infection or auto-immune disorders
• Use of tobacco products
• unexplained or intended weight loss of > 2 kg during the previous six months
• Surgery within the previous three months

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Purdue University

OTHER

Sponsor Role: lead

Principal Investigators

Robert E Hannemann, MD

Role: PRINCIPAL_INVESTIGATOR

Purdue University

Michael G Flynn, PhD

Role: STUDY_DIRECTOR

Purdue University

Locations

Purdue University

West Lafayette, Indiana, United States

Countries

United States

References

Stewart LK, Flynn MG, Campbell WW, Craig BA, Robinson JP, McFarlin BK, Timmerman KL, Coen PM, Felker J, Talbert E. Influence of exercise training and age on CD14+ cell-surface expression of toll-like receptor 2 and 4. Brain Behav Immun. 2005 Sep;19(5):389-97. doi: 10.1016/j.bbi.2005.04.003.

Reference Type: BACKGROUND

PMID: 15963685 (View on PubMed)

McFarlin BK, Flynn MG, Campbell WW, Stewart LK, Timmerman KL. TLR4 is lower in resistance-trained older women and related to inflammatory cytokines. Med Sci Sports Exerc. 2004 Nov;36(11):1876-83. doi: 10.1249/01.mss.0000145465.71269.10.

Reference Type: BACKGROUND

PMID: 15514501 (View on PubMed)

Methe H, Kim JO, Kofler S, Nabauer M, Weis M. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1439-45. doi: 10.1161/01.ATV.0000168410.44722.86. Epub 2005 Apr 28.

Reference Type: BACKGROUND

PMID: 15860745 (View on PubMed)

Related Links

http://www.irb.purdue.edu/

Committee on the use of Human Research Subjects at Purdue University

Other Identifiers

IRB Protocol Ref.#: 0504001888

Identifier Type: -

Identifier Source: secondary_id

0HQ01

Identifier Type: -

Identifier Source: org_study_id